BE543567A - - Google Patents
Info
- Publication number
- BE543567A BE543567A BE543567DA BE543567A BE 543567 A BE543567 A BE 543567A BE 543567D A BE543567D A BE 543567DA BE 543567 A BE543567 A BE 543567A
- Authority
- BE
- Belgium
- Prior art keywords
- piperazine
- pyridoxine
- compositions
- therapeutic composition
- hydrochloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 150000004885 piperazines Chemical class 0.000 claims description 7
- 229960002862 pyridoxine Drugs 0.000 claims description 6
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 230000001225 therapeutic Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 229960004172 Pyridoxine Hydrochloride Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 description 6
- -1 benzhydryl group Chemical group 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940066771 systemic antihistamines Piperazine derivatives Drugs 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N Benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229930003629 Vitamin B6 Natural products 0.000 description 2
- 229940011671 Vitamin B6 Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N Benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE543567A true BE543567A (ko) |
Family
ID=171838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE543567D BE543567A (ko) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE543567A (ko) |
-
0
- BE BE543567D patent/BE543567A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233853B1 (fr) | Couples effervescents, compositions effervescentes d'antagonistes H2 de l'histamine les contenant et leur préparation | |
| BE1005691A4 (fr) | Composition pharmaceutique a base de ranitidine et son procede de preparation. | |
| CH679011A5 (ko) | ||
| EP0914124B1 (fr) | COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE | |
| EP1108424B2 (fr) | Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale | |
| WO2000066130A1 (fr) | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel | |
| CA2123232C (fr) | Compositions pharmaceutiques a base d'ebastine ou de ses analogues | |
| BE1005115A5 (fr) | Compositions pharmaceutiques contenant des derives de furanne. | |
| JPH01193224A (ja) | モクソニジンを含有する製薬学的組成物及びその製造法 | |
| BE543567A (ko) | ||
| FR2604902A1 (fr) | Compositions pharmaceutiques a liberation prolongee | |
| EP0412901B1 (fr) | Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale | |
| EP1030671A1 (fr) | Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer | |
| EP1358159B1 (fr) | Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations | |
| BE1004182A3 (fr) | Compositions pharmaceutiques contenant un compose a activite agoniste selective aux recepteurs analogues a la 5-ht1. | |
| FR2544614A1 (fr) | Nouvelle association medicamenteuse pour le traitement de l'hypertension | |
| BE1003959A5 (fr) | Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale. | |
| EP0950050B1 (fr) | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues | |
| FR2525900A1 (fr) | Compositions therapeutiques a base de nouvelles argiles modifiees | |
| EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
| FR2691630A1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| FR2648710A1 (fr) | Composition pharmaceutique a base de ranitidine et son procede de preparation | |
| WO2013114416A1 (en) | Lyophilized tablets of escitalopram oxalate for sublingual administration | |
| CH660189A5 (fr) | Sels de dioxyde de benzothiazine cristallin et compositions pharmaceutiques les contenant. | |
| FR2464071A1 (fr) | Preparation pharmaceutique a base de dihydro-ergotamine et d'heptaminol |